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AbstrACt
background Ovarian cancers often contain significant 
numbers of tumor- infiltrating lymphocytes (TILs) that can be 
readily harnessed for adoptive T- cell therapy (ACT). However, 
the immunosuppressive ovarian tumor microenvironment 
and lack of tumor reactivity in TILs can limit the effectiveness 
of the therapy. We hypothesized that by using an oncolytic 
adenovirus (Ad5/3- E2F- D24- hTNFa- IRES- hIL2; TILT-123) to 
deliver tumor necrosis factor alpha (TNFa) and interleukin-2 
(IL-2), we could counteract immunosuppression, and 
enhance antitumor TIL responses in ovarian cancer (OVCA).
Methods We established ex vivo tumor cultures freshly 
derived from patients with advanced OVCA and evaluated 
the effects of Ad5/3- E2F- D24- hTNFa- IRES- hIL2 or Ad5/3- 
E2F- D24 (the control virus without TNFa and IL-2) on TILs, 
cytokine response and tumor viability. Tumor reactivity was 
assessed by determining interferon gamma (IFNg) response 
of clinically relevant TILs towards autologous T- cell- depleted 
ex vivo tumor cultures pretreated with or without the 
aforementioned oncolytic adenoviruses.
results Treatment of ex vivo tumor cultures with Ad5/3- 
E2F- D24- hTNFa- IRES- hIL2 caused a substantial rise in 
proinflammatory signals: increased secretion of IFNg, 
CXCL10, TNFa and IL-2, and concomitant activation of 
CD4+ and CD8+ TILs. Potent tumor reactivity was seen, 
as clinically relevant TIL secreted high levels of IFNg in 
response to autologous T- cell- depleted ovarian ex vivo tumor 
cultures treated with Ad5/3- E2F- D24- hTNFa- IRES- hIL2. 
This phenomenon was independent of PD- L1 expression in 
tumor cells, a factor that determined the variability of IFNg 
responses seen in different patient samples.
Conclusions Overall, oncolytic adenovirus Ad5/3- E2F- 
D24- hTNFa- IRES- hIL2 was able to rewire the ovarian tumor 
microenvironment to accommodate heightened antitumor TIL 
reactivity. Such effects may improve the clinical effectiveness 
of ACT with TILs in patients with advanced OVCA.
bACkground
Tumor progression is often mediated by 
dysfunctional antitumor T cells in advanced 
or metastatic solid cancers.1 This scenario 
is evident when disease progression occurs 
despite the natural existence of tumor- reactive 
CD4+ and CD8+ tumor- infiltrating lympho-
cytes (TIL) at the tumor site. Nevertheless, 
the existence of naturally occurring TILs has 
been linked to improved treatment outcome 
in a number of cancers2 3 posing an oppor-
tunity for harnessing tumor- reactive TILs for 
therapeutic purposes. A potent strategy to 
achieve this relies on the ex vivo generation 
and expansion of TILs, for infusion back into 
the same patient in the setting of adoptive 
T- cell therapy (ACT).4
In heavily pretreated patients with meta-
static melanoma, TIL transfer has led to 
objective response rates up to 70%, and they 
are regularly seen in about half of patients.5–7 
Complete responses are seen in about one 
in four patients, and they tend to be lasting.7 
However, these responses are yet to be repro-
duced in other solid tumor indications, 
including ovarian cancer (OVCA).
The previous clinical data on OVCA TIL 
therapy are controversial. The reports agree 
that TILs can be abundant and expansion for 
therapeutic application is feasible, but clinical 
efficacy has been variable. One small clinical 
study reported up to 82% objective response 
rate in stage III–IV OVCA.8 In other studies, 
short- term disease stabilization was the best 
outcome.9 10
The presence of an established suppres-
sive network that dampens tumor- specific 
CD4+ and CD8+ TILs is a feature of the 
tumor microenvironment of OVCAs, which 
can decrease the clinical effectiveness of TIL 
therapy.11 12 Infiltration by myeloid- derived 
suppressor cells (MDSC) and regulatory T 
cells (Tregs) has been directly linked to poor 
prognosis in OVCA.2 13 Together, these cell 
types suppress tumor- specific TIL immunity 
through a range of mechanisms including, 
copyright.














2 Santos JM, et al. J Immunother Cancer 2020;8:e000188. doi:10.1136/jitc-2019-000188
Open access 
Table 1 Characteristics of patients with ovarian cancer




OVCA #1 65 Ovarian low- grade serous 
carcinoma St IVB
– Metastasis Greater 
omentum
80%
OVCA #2P 71 Ovarian high- grade serous 
carcinoma St IIIC
– Primary Ovary 70%
OVCA #2M Metastasis Greater 
omentum
N/A 






OVCA #4 50 Ovarian high- grade serous 
carcinoma St IIIC
– Primary Ovary 95%
OVCA #5 39 Ovarian clear cell carcinoma St 
IVB
– Primary Ovary 80%
OVCA #6 72 Ovarian clear cell carcinoma St 
IIIC
– Primary Ovary 90%
*at date of resection.
BRCA, breast cancer gene; ID, identification; N/A, not assessed; OVCA, ovarian cancer; St, stage.
but not limited to, the secretion of immunosuppressive 
cytokines.13 14 On the other hand, given the mutanome of 
OVCA, other studies have attributed the lack of efficacy 
to fewer TIL clones directed against strong tumor- derived 
antigens, such as neoantigens.10
Viral infections are capable of inducing powerful T- cell 
immunity.15 In cancer immunotherapy, this notion has 
been used to develop therapeutic viruses that replicate 
and induce immunogenic death in tumor cells, and 
amplify T- cell- mediated antitumor immunity.16 In partic-
ular, adenoviruses stand out for their ability to generate 
new T- cell responses against known tumor antigens17 and 
neoantigens18 in cancer- bearing humans, as well as in 
preclinical models.19 Moreover, oncolytic adenoviruses 
can be modified to harbor transgenes coding for immune 
stimulatory cytokines, allowing for further customization 
and amplification of the antitumor immune response.
In the tumor microenvironment of OVCA, the delivery 
of tumor necrosis factor alpha (TNFa) and interleukin-2 
(IL-2) by an oncolytic adenovirus (Ad5/3- E2F- D24- 
hTNFa- IRES- hIL2; TILT-123) could spark a much needed 
immunological stimulus. This could invigorate TIL 
activity in the context of ACT, as shown in melanoma and 
pancreatic cancer.20 This is further supported by efficacy 
data from patient cohorts, where patients with OVCA 
appeared to benefit from oncolytic adenovirus therapy.21 
Importantly, among a panel of FDA- approved cytokines, 
TNFa and IL-2 was the combination of cytokines that 
best synergized with antitumor T cells in our preclinical 
studies.22 23 This translated into promising safety, effi-
cacy and survival results in animals bearing melanoma 
and pancreatic tumors, following adoptive transfer of 
TILs,20 T- cell receptor- engineered T cells22 and chimeric 
antigen receptor T cells.24 Such outcome is attributed 
to a decrease in intratumororal immunosuppression 
and, improved trafficking and activation of transferred 
T cells. Notably, this approach also seems promising in 
the context of unleashing T cells with checkpoint inhib-
itors.25 26
Thus, we studied the possibility of using TNFa and IL-2- 
coding oncolytic adenovirus to restore and enhance the 
tumor reactivity of TILs in the context of immunosup-
pressive human OVCA. We established patient- derived 
ex vivo tumor cultures and studied how the introduc-
tion of TNFa and IL-2 by an oncolytic virus, reshapes the 
overall cytokine response and activation status of TILs 
in the tumor microenvironment. We then studied the 
consequences of such immune modulation on the anti-
tumor reactivity of TILs, by transferring clinically relevant 
TILs into autologous adenovirus- infected human OVCA 
single- cell suspensions depleted of endogenous T cells.
Methods
Patient material
OVCA samples were collected from six patients under-
going surgical resection at the Helsinki University Central 
Hospital (Helsinki, Finland). Almost all patients included 
in the study were treatment naïve, with exception of 
patient OVCA #3 who had previously received three 
rounds of taxane- platinum neoadjuvant chemotherapy 
prior to surgery (table 1).
oncolytic adenoviruses
The viruses used in this study were generated using 
genetic editing strategies previously described by our 
group. Briefly, Ad5/3- E2F- D24 was generated by cotrans-
fecting PacI/PmeI- linearized pShuttleΔ24 (plasmid 
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Figure 1 Cytokine modulation in ex vivo tumor cultures during oncolytic adenovirus therapy. Supernatants from patient ex 
vivo tumor cultures were harvested on day 3 and day 6 or 7 for analysis of interleukin-2 (IL-2), tumor necrosis factor alpha 
(TNFa), interferon gamma (IFNg), C- X- C motif chemokine 10 (CXCL10), interferon beta (IFNb) (proinflammatory cytokines) 
and interleukin-6 (IL-6), arginase and transforming growth factor beta-1 (TGF- b1) (suppressive cytokines). IL-2 was initially 
described as T- cell growth factor, while CXCL10 is a potent T- cell recruitment factor. (A) IL-2, TNFa, IFNg, CXCL10, IFNb 
concentration at day 3 and (B) day 6 or 7 and (C) normalized pooled proinflammatory cytokine changes. (D) IL-6, arginase 
and TGF- b1 concentration on day 3 and (E) day 6 or 7 and (F) normalized pooled suppressive cytokine changes. (G) Ratio 
of proinflammatory versus suppressive normalized pooled cytokine subsets. Each patient experiment was performed in 
quadruplicate and data are shown as mean+SEM. Statistical significance is represented as *p<0.05. Dashed line shows the 
level in vehicle- treated samples (100%).
containing E1A with a 24 bp deletion in the CR2 region) 
with PacI- linearized pTU.5/3 (a plasmid containing an 
E1A- deleted chimeric ad5 genome) in 911 cells. The 
resulting plasmid was transfected and propagated in A549 
cells.27 To generate Ad5/3- E2F- D24- hTNFa- IRES- hIL2, 
we inserted the cytokine transgenes in the E3 region of 
Ad5/3- E2F- D24 using bacterial artificial chromosome- 
recombineering strategy based on the selection marker 
galK.20 Both viruses were manufactured using a cesium 
chloride gradient and the concentration was determined 
by optical density at 260 nm.
sample processing, establishment of ex vivo and in vitro 
tumor cultures
Fresh single- cell tumor digests were prepared from 
OVCA tumors using a protocol previously validated by 
our group.28 In brief, OVCA tumors were diced into small 
fragments and placed in a 50 mL falcon tube containing 
RPMI 1640 (Sigma- Aldrich, Missouri, USA) supple-
mented with 1% L- glutamine, 1% Pen/strep (Gibco, 
Thermo Fisher Scientific, Massachusetts, USA), collage-
nase type I (170 mg/L), collagenase type IV (170 mg/L), 
DNase I (25 mg/mL) and elastase (25 mg/mL) (all 
enzymes from Worthington Biochemical) for overnight 
enzymatic digestion with rocking at +37°C. After diges-
tion, the cell suspension was filtered through a 100 μm 
filter and treated with Ammonium- Chloride- Potassium 
lysis buffer (Sigma- Aldrich) for the removal of undi-
gested fragments and red cells. The resulting single- cell 
suspension was used to establish ex vivo tumor cultures by 
plating fresh 0.35×106 cells in a 96- well plate and treated 
with multiplicity of infection (MOI; herein defined as 
virus particle/cell) 100 of Ad5/3- E2F- D24, Ad5/3- E2F- 
D24- TNF- IRES- IL-2 (TILT-123) or medium (vehicle). 
The remaining tissue was collected in freezing medium 
containing 90% fetal bovine serum (FBS) and 10% 
dimethyl sulfoxide and stored up to −140°C until further 
use. Alternatively, human ovarian adenocarcinoma cell 
line expressing luciferase- firefly SK- OV-3- LUC (kindly 
provided by Dr Negrin, Stanford Medical School) was 
established and grown in complete Dulbecco’s modified 
Eagle’s medium supplemented with 10% FBS, 1% L- glut 
and 1% Pen/strep.
Cytotoxicity assay
The cell viability of OVCA ex vivo tumor cultures was 
determined in accordance with a protocol previously 
described by our group.28 Briefly, cell viability was verified 
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at days 3 and 6 or 7 by incubating 2–3 hours 50 μL of 
CellTiter 96 AQueous One Solution Proliferation Assay 
reagent (Promega, Wisconsin, USA). Absorbance was 
read at 492 nm using a Fluostar OPTIMA analyzer (BMG 
Labtech, Offenburg, Germany). Each time data point was 
normalized to the vehicle control group.
Cytokine expression and virus propagation assay
0,01×106 SK- OV-3- LUC was seeded and incubated over-
night in a 96- well plate. The following day different MOIs 
of Ad5/3- E2F- D24- TNF- IRES- IL-2 were added to culture. 
After 72 hours, supernatant from cultures was collected 
in protease inhibitor and stored at −20°C until anal-
ysis. Concomitantly, cells were collected in phosphate- 
buffered saline and their DNA was extracted with QIAmp 
DNA Mini Kit (Qiagen, the Netherlands) according 
to the manufacturer’s instructions. Virus presence was 
confirmed by quantitative PCR targeting the d24 dele-
tion of the E1A region using forward primer (5′- TCCG 
GTTT CTAT GCCA AACCT-3′), reverse primer (5′- TCCT 
CCGG TGAT AATG ACAAGA-3′) and probe (5′FAM- 
TGATCGATCCACCCAGTGA-3′MGBNFQ). The results 
were normalized against the content of human b- actin 
housekeeping gene DNA, described elsewhere.29
Cytokine analysis
Supernatants from the treated OVCA ex vivo tumor 
cultures were collected on days 3 and 6 or 7 in the pres-
ence or absence of protease inhibitor and stored at 
−80°C. The presence of interferon gamma (IFNg), TNFa, 
IL-2, interferon beta (IFNb), C- X- C motif chemokine 
10 (CXCL10), interleukin 6 (IL-6), arginase, and trans-
forming growth factor beta-1 (TGF- b1) content was deter-
mined through a custom LEGENDplex panel and a free 
active/total TGF- b1 detection kit (Biolegend, California, 
USA) in agreement with the manufacturer’s recommen-
dations. The levels of TNFa and IL-2 in supernatants from 
SK- OV-3- LUC cells were determined through human IL-2 
and TNFa flex sets (BD Biosciences, California, USA). 
Samples were measured using Accuri C6 flow cytom-
eter (BD Biosciences) and analyzed through LEGEND-
plex V.8.0 software (VigeneTech, Massachusetts, USA) 
or FCAP Array software (BD Biosciences). When appro-
priate, data obtained were normalized to vehicle control 
group and data points outside of the standard curves 
were extrapolated according to the software predictions 
and only considered when at least four values inside the 
standard curve could be retrieved in one of the analyzed 
days. The figure 1C,FThe normalized levels of pooled 
proinflammatory and suppressive cytokines derive from 
a three- step procedure: (1) each patient’s individual cyto-
kine average concentration value of the different thera-
peutic groups was normalized against the vehicle control, 
(2) each patient’s individual normalized cytokine values 
were summed according to their category (proinflamma-
tory or suppressive) and the average of each therapeutic 
group was calculated, and (3) the sum of each patient’s 
grouped cytokines normalized values we renormalized 
against the vehicle control group. The values shown in 
the graph are the averages of each therapeutic group.
generation and expansion of tILs
TILs were propagated from patient samples using a vari-
ation of the ‘young TILs’ protocol described elsewhere.30 
Tumor samples were excised into 1–5 mm3 fragments 
which were placed into six- well G- rex culturing plates 
(Wilson Wolf, Minnesota, USA) filled with 30 mL of TIL 
medium (TM) containing RPMI 1640 supplemented 
with 20% FBS, 1% L- glutamine, 1% Pen/strep, 15 mM 
HEPES, 1 mM Na- pyruvate, 50 μm b- mercaptoethanol 
(Sigma- Aldrich) and 3000 IU/mL recombinant human 
IL-2 (PeproTech, Sweden). Subsequently, the cells were 
incubated for 5 days in a humidified incubator at +37°C. 
At day 5, half of the medium was replaced with fresh TM 
and further incubated until day 7, in which TILs were 
collected in freezing medium and stored up to −140°C 
until further use. Upon collection of five patient tumor 
samples, 0.8–1.25×106 TILs were thawed and rested for 
2 days in TM for subsequent rapid expansion. On day 0, 
half of the culture medium was replaced with irradiated 
(40 Gy) allogeneic (four donors) feeder peripheral blood 
mononuclear cells (PBMC) (1:200 TIL:PBMC ratio), 
OKT3 antibody (30 ng⁄mL; eBioscience, Thermo Fisher 
Scientific) and rapid expansion medium (RM) containing 
20% FBS, 1% L- glut, 1% Pen/strep and 3000 IU/mL 
recombinant IL-2. On day 5, half of the medium was 
replaced by a 1:1 mixture of TM and RM. By day 7, 75% 
of the medium was aspirated (while retaining the cells 
in the bottom) and the number of TILs was adjusted to 
5−10×106 TILs/cm2 every 3–4 days until day 14.
Autologous tIL-tumor cocultures
OVCA single- cell suspensions were depleted from CD3+ 
cells using CD3 MicroBeads (Miltenyi Biotec, Germany) 
and 0.85×106 cells were incubated with MOI 100 of 
Ad5/3- E2F- D24, Ad5/3- E2F- D24- TNF- IRES- IL-2 (TILT-
123) or medium in 24- well plates on day 0. On day 1, 
fresh 0.85×106 autologous expanded TILs were washed 
twice with growth medium, added to culture and incu-
bated for 6 additional days in a humidified incubator at 
+37°C. Endpoint supernatant and cells were collected 
for the detection of IFNg and analysis of T- cell markers, 
respectively.
IFng eLIsA
Supernatants from days 2, 5 and 7 of the TIL- tumor cocul-
tures were collected and detection of IFNg was performed 
using ELISA MAX Deluxe Set Human IFNg (Biolegend) 
following the manufacturer’s instructions. Absorbance 
was read at 450 nm using a Fluostar OPTIMA analyzer 
(BMG Labtech, Offenburg, Germany) and values were 
interpolated using a line as standard curve with GraphPad 
Prism V.8software (GraphPad, La Jolla, CA, USA).
Flow cytometry
Cells from the ex vivo tumor cultures were collected on days 
3 and 7 and stained with PE- labelled anti- EpCAM, Alexa 
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Figure 2 Lytic capability of oncolytic adenovirus in ovarian cancer patient ex vivo tumor cultures. (A) Tumor digests (containing 
cancer cells, stromal cells and immune cells) were obtained fresh from patients with resected ovarian cancer and cultured 
for 6–7 days with multiplicity of infection (MOI) 100 of oncolytic virus. Viability was assessed on the indicated days. (B) OVCA 
#2M, (C) OVCA #2P, (D) OVCA #3, (E) OVCA #4, (F) OVCA #5 and (G) OVCA #6. Each patient experiment was performed in 
quadruplicate and data are shown as mean+SEM. Statistical significance is represented as *p<0.05, **p<0.01, ***p<0.001, and 
****p<0.0001. OVCA, ovarian cancer.
Fluor 700- labelled anti- CD45, PE/Dazzle 594- labelled 
anti- CD69, PE- Cy7- labelled anti- programmed death 
ligand 1 (PD- L1) (Biolegend), PerCP- Cy5.5- labelled 
anti- CD4, FITC- labelled anti- CD8 and APC- labelled anti- 
CD25 (eBioscience, Thermo Fisher Scientific) according 
to the manufacturer’s instructions. Cells from expanded 
TILs or autologous TIL- tumor coculture were collected 
at day 6 and stained with PE- labelled anti- FoxP3, PE/
Dazzle 594- labelled anti- CD3, APC/Cy7- labelled anti- 
CD16 and anti- PD-1, APC- labelled anti- CD56 (Biolegend) 
and anti- CD25, PerCP- Cy5.5- lablled anti- CD4, FITC- 
labelled anti- CD8 (eBioscience, Thermo Fisher Scien-
tific), PE- Cy7- labelled anti- CD27 (BD Biosciences). A 
total of 10,000–100,000 events were acquired using FACS 
Aria II cell sorter (BD Biosciences) and data analysis was 
performed using FlowJo software V.10 (FlowJo, BD Biosci-
ences). Geometric mean data from activation markers 
were normalized to the vehicle group.
histopathology
After resection, OVCA tissue was fixed, paraffin embedded 
and cut into 4–5 μm slides either for H&E staining or 
immunohistochemistry. Anti- PD- L1 (Abcam, UK) was 
stained using Lab Vision Autostainer (Thermo Fisher 
Scientific). Anti- CD8 (Novocastra, Leica Biosystems, Illi-
nois, USA) and anti- CD4 (Cell Marque, Merck, California, 
USA) were stained using a VENTANA Autostainer (Roche, 
Switzerland). PD- L1 expression was scored based on the 
frequency of PD- L1+ tumor cells. The score is as follows: 
0=<1%, 1=1%–4%, 2=5%–9%, 3=10%–49%, 4=>50% of 
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PD- L1+ tumor cells. CD8+ and CD4+ cells were counted 
using high- power field at 400×. Tumor histologies, breast 
cancer (BRCA) gene mutated tumor cell frequencies, 
CD8+ and CD4+ cell count and PD- L1 scores were provided 
and confirmed by a gynecological pathologist.
statistical analysis
Differences between treatment groups were studied 
by unpaired Student’s t- test with Welch’s correction 
while correlations between variables were investigated 
using Spearman non- parametric correlation, both using 
GraphPad Prism V.8 software (GraphPad, La Jolla, CA, 
USA).
resuLts
oncolytic adenovirus therapy reduces the viability of oVCA 
patient ex vivo tumor cultures
We have previously shown that Ad5/3- E2F- D24- hTNFa- 
IRES- hIL2 is able to replicate and lyse human OVCA cell 
lines.20 However, it remained unclear how this phenom-
enon is affected by virus- derived cytokines and cell subsets 
present in the tumor microenvironment of different types 
and stages of OVCA. Therefore, ex vivo tumor cultures 
from five patients with OVCA bearing tumors with diverse 
histologies were established up to 7 days (figure 2A). 
Treatment with Ad5/3- E2F- D24 (control without trans-
genes) or Ad5/3- E2F- D24- hTNFa- IRES- hIL2 exerted 
similar antitumor killing profiles in most patient ex vivo 
tumor cultures.
By day 3, Ad5/3- E2F- D24 or Ad5/3- E2F- D24- hTNFa- 
IRES- hIL2 had significantly decreased the viability of most 
cultures to values ranging from 95% to 60% relative to the 
vehicle control. In detail, Ad5/3- E2F- D24 was more effec-
tive in killing ex vivo tumor cultures from samples OVCA 
#3 (p<0.01) and OVCA #5 as compared with Ad5/3- E2F- 
D24- hTNFa- IRES- hIL2 (figure 2B). However, the latter 
was capable of decreasing the viability of OVCA #2P ex 
vivo tumor cultures slightly faster than Ad5/3- E2F- D24 
therapy. Such difference is inverted by day 6, when treat-
ment with Ad5/3- E2F- D24 drops the viability of the ex vivo 
tumor culture to 30% compared with 60% in the Ad5/3- 
E2F- D24- hTNFa- IRES- hIL2 therapy group (figure 2B). 
A similar scenario is observed on day 7 in OVCA #4 ex 
vivo tumor cultures where a marginal reduction, although 
statistically significant (p<0.01), was more prominent 
in wells treated with Ad5/3- E2F- D24 relative to Ad5/3- 
E2F- D24- hTNFa- IRES- hIL2 treated wells (figure 2B). 
Surprisingly, therapy with Ad5/3- E2F- D24 or Ad5/3- E2F- 
D24- hTNFa- IRES- hIL2 was only able to cause reduction of 
10% viability in OVCA #5 ex vivo tumor culture, which 
could reflect the limitations of the assay (figure 2B). Of 
note, the virus is only able to kill malignant cells, while 
normal cells including TILs would remain unharmed.
Cytokine-coding adenovirus therapy induces 
extensive immunostimulatory modulation in the tumor 
microenvironment
Over 6–7 days of culturing period, treatment of OVCA 
patient ex vivo cultures with cytokine- coding oncolytic 
adenoviruses caused changes in the immunological status 
of the tumor microenvironment, which was reflected in the 
production of several cytokines. This is possible because 
OVCA cells can manufacture IL-2 and TNFa. We saw a 
dose- dependent increase in the levels of these cytokines 
(online supplementary figure 1A) and virus DNA (online 
supplementary figure 1B) when we infected an ovarian 
adenocarcinoma cell line with increasing amounts of 
Ad5/3- E2F- D24- hTNFa- IRES- hIL2. Furthermore, a signif-
icant positive correlation was found between the levels 
of DNA and TNFa (online supplementary figure 1C; 
r=0.9821 (0.9438 to 0.9944), p<0.0001) and IL-2 (online 
supplementary figure 1D; r=0.9491 (0.8454 to 0.9838), 
p<0.0001). Hence, during infection with Ad5/3- E2F- D24- 
hTNFa- IRES- hIL2, the levels of these cytokines were very 
high on day 3 as compared with the vehicle or Ad5/3- 
E2F- D24 treated groups (figure 1A). These differences 
remain consistent on day 6+ (figure 1B), with a slight 
increase in both cytokines relative to day 3. Ad5/3- E2F- 
D24- hTNFa- IRES- hIL2 therapy also induced the produc-
tion of IFNg and CXCL10 which, in contrast with the 
vehicle and Ad5/3- E2F- D24 treated groups, had a peak in 
production at day 6+ (figure 1B).
Of note, production of CXCL10 by day 6+ had 
increased in all therapeutic groups (figure 1B). Interest-
ingly, treatment with oncolytic adenovirus caused only a 
negligible increase in IFNb production, although levels 
were steadily higher in groups treated with Ad5/3- E2F- 
D24- hTNFa- IRES- hIL2 compared with the vehicle and 
Ad5/3- E2F- D24. Thus, the overall presence of proinflam-
matory signals in patient ex vivo tumor cultures treated 
with cytokine- coding adenoviruses differed significantly 
from vehicle and Ad5/3- E2F- D24 on day 3 (1407- fold 
and 874- fold differences, respectively) and day 6+ (2256- 
fold and 1350- fold differences, respectively, both p<0.05) 
(figure 1C). This pool of proinflammatory (with TNFa 
and IL-2) signals was found to be negatively correlated 
with tumor histoculture viability (r=−0.6427 (−0.8055 
to −0.3897), p<0.0001). Because TNFa and IL-2 may be 
from viral origin, we considered excluding these from the 
proinflammatory cytokine pool. Still, excluding the levels 
of these cytokines from the proinflammatory pool (thus 
only with IFNg, CXCL10, IFNb) the ratio was still high on 
day 6+, in cultures treated with Ad5/3- E2F- D24- hTNFa- 
IRES- hIL2, as compared with the unarmed virus or 
vehicle control group (2.5- fold and 5.1- fold differences, 
respectively) (online supplementary figure 1E).
In contrast, fewer differences were observed in the 
levels of factors with suppressive potential, such as IL-6, 
arginase and TGF- b1. On day 3, treatment with Ad5/3- 
E2F- D24- hTNFa- IRES- hIL2 increased IL-6 relative to the 
vehicle and Ad5/3- E2F- D24 which stayed at approximately 
the same level (figure 1D). Conversely, Ad5/3- E2F- D24 
and Ad-5/3- E2F- D24- hTNFa- IRES- hIL2 treatment 
lowered IL-6 relative to the vehicle control (figure 1E). 
In comparison with vehicle and Ad5/3- E2F- D24, a trend 
for reduced presence of arginase and TGF- b1 was found 
in ex vivo tumor cultures treated with cytokine- coding 
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oncolytic adenoviruses on days 3 and 6+. In the latter, 
a total reduction of suppressive signals was observed on 
oncolytic adenovirus therapy compared with the vehicle 
control (figure 1F).
No correlation was found between pooled suppressive 
cytokines and the reduction of tumor ex vivo tumor culture 
viability. In the Ad5/3- E2F- D24- hTNFa- IRES- hIL2 group, 
these changes resulted in a proinflammatory/suppressive 
ratio of 2713.42, compared with approximately 2.1 and 
1.0 for Ad5/3- E2F- D24 and vehicle control, respectively, 
on day 6+ (figure 1G). These differences were observed 
to a lower extent when TNFa and IL-2 were excluded 
from the pooled levels (online supplementary figure 1F).
Activation of Cd4+ and Cd8+ tILs is improved during 
virotherapy-mediated immune modulation
The tumor microenvironment of human OVCA is 
distinctly characterized by the presence of inactivated TILs 
which can be readily harnessed if an appropriate stimulus 
is introduced. Here, treatment of patient ex vivo tumor 
cultures with TNFa and IL-2 coding oncolytic adenovi-
ruses induced several changes in TIL activation that were 
not observed in other treatment groups. Comparative to 
vehicle and Ad5/3- E2F- D24, the use of cytokine- coding 
oncolytic adenovirus increased the overall presence of 
CD69 in CD8+ TILs (online supplementary figure 2A), in 
agreement with statistically significant increases observed 
in three out of five samples on day 6+ (figure 3A). On 
the same day, CD8+ TILs expressed higher levels of CD69 
in groups treated with oncolytic adenoviruses relative 
to the vehicle control, which was particularly notable in 
the Ad5/3- E2F- D24 treatment group on day 6+ (online 
supplementary figure 2B). When analyzed sample by 
sample, increase in CD69 expression in CD8+ TILs was 
only seen for OVCA #5, in which the difference was statis-
tically significant (Ad5/3- E2F- D24 vs Ad5/3- E2F- D24- 
hTNFa- IRES- hIL2, p<0.05). For the majority of samples 
only a trend for its increased expression was seen on 
Ad5/3- E2F- D24- hTNFa- IRES- hIL2 therapy (figure 3B). 
Overall, expression of CD69 in CD8+ TILs was not asso-
ciated with the secretion of proinflammatory cytokines 
(r=0.007274 (−0.5192 to 0.5297), p=0.9844; figure 3C).
With regard to the presence of CD4+CD69+ TILs, 
on day 6+, a mild reduction was observed during onco-
lytic adenovirus therapy in comparison with the vehicle 
control group (online supplementary figure 2C). 
Although not statistically significant, this reduction was 
more prominent in the Ad5/3- E2F- D24 treated group 
(three out of five samples) followed by Ad5/3- E2F- D24- 
hTNFa- IRES- hIL2 treatment group (figure 3D). The 
latter induced CD69 expression in CD4+ TILs on days 
3 and 6 as opposed to the vehicle and Ad5/3- E2F- D24 
(online supplementary figure 2D). Similarly, the upreg-
ulation of CD69 in CD4+ TILs was statistically higher in 
three out of five samples following infection with Ad5/3- 
E2F- D24- hTNFa- IRES- hIL2 (figure 3E). Interestingly, 
this upregulation was positively correlated with the pres-
ence of proinflammatory cytokines (r=0.8547 (0.5985 to 
0.9523), p<0.0001; figure 3F), and may be associated with 
a helper phenotype of these cells.
Concerning the percentage of CD4+CD25+ TILs, an 
overall increase in this subset was observed on day 6+, 
however, the increase was more prominent when no 
treatment was applied (online supplementary figure 
2E). In particular, Ad5/3- E2F- D24- hTNFa- IRES- hIL2 
therapy significantly reduced this subset in three out of 
five samples while Ad5/3- E2F- D24 therapy induced such 
reduction in two out of five samples (figure 3G). Overall, 
the highest upregulation of CD25 was achieved on day 
3 during Ad5/3- E2F- D24 therapy (online supplementary 
figure 3F), and on day 6 during Ad5/3- E2F- D24- hTNFa- 
IRES- hIL2 (figure 3H). At a sample level, this trend was 
seen in two out of five patients on day 6+ (online supple-
mentary figure 2F). These cells were not correlated with 
suppressive cytokines (r=0.1818 (−0.3788 to 0.6448), 
p=0.5163; figure 3I).
Antitumor reactivity of clinically relevant tILs is improved by 
cytokine-coding oncolytic adenovirus
Considering the shift in the immune status of the tumor 
microenvironment on cytokine- coding oncolytic adeno-
virus treatment, we set out to evaluate whether such 
modulation positively favors antitumor reactivity in the 
context of TIL therapy. Thus, CD3- depleted single- cell 
suspensions treated with or without oncolytic adeno-
virus were cocultured with autologous expanded TILs 
from patients with OVCA (figure 4A). The TIL product 
contained a CD3+ fraction which comprised CD8+ TILs in 
its majority (65.5%), followed by CD4+ TILs (26.4%) and 
CD3+CD56+ natural killer (NK) T cells (3.3%). The CD3− 
fraction included 14.8% NK cells, at day 14 (figure 4B). 
The culturing conditions also allowed the presence of 
CD4+CD25+FoxP3+ Tregs, with their frequency reaching 
a maximum of 1.78% in OVCA #1 TILs and a minimum 
of 0.29% in OVCA #2M, in the CD4+ fraction (online 
supplementary figure 3A). The presence of CD27+ 
TILs was significantly enriched in the CD8+ fraction as 
compared with the CD4+ fraction (CD3+CD8+CD27+ 
vs CD3+CD4+CD27+; p<0.005). No differences were 
found regarding CD62L+ TILs (figure 4C).
Following the addition of autologous TILs, IFNg produc-
tion was highest in two out of six samples in response to 
Ad5/3- E2F- D24- hTNFa- IRES- hIL2 (figure 4D) on day 
2. IFNg peaked for the same samples (OVCA #2M and 
OVCA #4) on day 5, during a time which new statistically 
relevant antitumor reactivity emerged in two additional 
samples (OVCA 3 and OVCA #5, both p<0.05, figure 4E). 
A similar situation occurred in OVCA #2P on day 7, 
where, compared with Ad5/3- E2F- D24 treatment, Ad5/3- 
E2F- D24- hTNFa- IRES- hIL2 therapy induced new statisti-
cally (p<0.05) relevant reactivity (figure 4F). Additionally, 
during Ad5/3- E2F- D24- hTNFa- IRES- hIL2 therapy, differ-
ences in IFNg production became more apparent in 
sample OVCA #3, due to the significant reduction of IFNg 
secretion in the vehicle control (p<0.01) and Ad5/3- 
E2F- D24 (p<0.01) groups. This indicated persistent 
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Figure 3 Presence and activation status of CD4+ and CD8+ tumor- infiltrating lymphocytes (TIL) in ex vivo tumor cultures 
at day 6. Cells from patient ex vivo tumor cultures were harvested on day 6 for analysis of CD69 (an early activation marker) 
and CD25 (interleukin-2 (IL-2) receptor) in CD8+ and CD4+ TILs. (A) Percentage of CD8+CD69+ TILs, (B) normalized mean 
fluorescence intensity (MFI; a measure of number of receptors at the surface of gated cells) of CD69 in CD8+ TILs, (C) 
correlation between CD69 MFI in CD8+ TILs and pooled proinflammatory cytokines from all therapeutic groups, (D) percentage 
of CD4+CD69+ TILs, (E) normalized MFI of CD69 in CD4+ TILs, (F) correlation between CD69 MFI in CD4+ TILs and pooled 
proinflammatory cytokines, (G) percentage of CD4+CD25+ TILs, (H) normalized MFI of CD25 in CD4+ TILs, (I) correlation 
between CD25 MFI in CD4+ TILs and pooled suppressive cytokines. Each patient experiment was performed in quadruplicate 
and data are shown as mean+SEM. Statistical significance is represented as *p<0.05, **p<0.01 and ***p<0.001. OVCA, ovarian 
cancer.
stimulatory effects of cytokine- coding oncolytic adenovi-
ruses on TILs (figure 4F). Of note, no statistically rele-
vant differences between treatment groups were found 
for sample OVCA #1, over the course of 7 days’ coculture. 
However, during the coculturing period, the antitumor 
reactivity of autologous TILs was enhanced on Ad5/3- E2F- 
D24- hTNFa- IRES- hIL2 therapy in five out of six samples. 
Despite the presence of Tregs after expansion of autolo-
gous TILs, we did not see a difference in the magnitude 
of IFNg response in the cocultures (r=0.03449 (−0.4515 
to 0.5046), p=0.8919; online supplementary figure 3B).
Virus-induced enhanced antitumor reactivity associates with 
Cd4+ tILs
In order to identify the source of the antitumor reac-
tivity seen, we set out to characterize the transferred 
TILs present in the TIL/tumor cocultures. By day 7, 
Ad5/3- E2F- D24- hTNFa- IRES- hIL2 therapy had substan-
tially increased the presence of CD8+ TILs over the 
vehicle control and Ad5/3- E2F- D24 treatment groups in 
sample OVCA #1, OVCA #3 and OVCA #4 (figure 5A). 
In sample OVCA #2P, this phenomenon extended to the 
Ad5/3- E2F- D24 treatment group, where the increase was 
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Figure 4 Characterization of expanded tumor- infiltrating lymphocytes (TIL) and reactivity assessment towards autologous 
tumor digests. (A) Excised tumor fragments from each patient were used for the generation and rapid expansion of TILs during 
14 days. These were subsequently cocultured with CD3- depleted autologous tumor digests in the presence or absence of 
oncolytic adenovirus and supernatants were collected for interferon gamma (IFNg) analysis. (B) Identification of CD3+CD8+ 
T cells, CD3+CD4+ T cells and CD56+CD16+ natural killer (NK) cells and (C) differentiation status markers, such as CD27 
(costimulatory molecule) and CD62L (adhesion molecule for secondary lymphoid structures). (D) Day 2 coculture IFNg levels. 
(E) Day 5 coculture IFNg levels. (F) Day 7 coculture IFNg levels. Each patient experiment was performed in triplicates and data 
are shown as mean+SEM. Statistical significance is represented as *p<0.05, **p<0.01 and ***p<0.001. Symbols are as follows: 
dots—OVCA #1, squares—OVCA #2M, triangles—OVCA #2P, diamonds—OVCA #3, hexagons—OVCA #4, hollow dots—OVCA 
#5. OVCA, ovarian cancer.
significant compared with the vehicle control group, and 
as high as in the Ad5/3- E2F- D24- hTNFa- IRES- hIL2 group 
(figure 5A). In the latter group, the presence of CD27 
was statistically reduced (p<0.05) in OVCA #1 compared 
with the vehicle control group (online supplementary 
figure 3C). Intriguingly, the increase of IFNg content 
in the wells strongly correlated with the decrease in the 
presence of CD8+ TILs (r=−0.4223 (−0.6249 to –0.1663), 
p=0.0015; figure 5B).
In a similar manner, the presence of CD4+ TILs in 
Ad5/3- E2F- D24- hTNFa- IRES- hIL2 treated wells was 
significantly higher relative to vehicle control and Ad5/3- 
E2F- D24 in samples OVCA #2M, OVCA #3 and OVCA 
#4. The same trend, although not statistically relevant, 
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Figure 5 Presence of tumor- infiltrating lymphocytes (TIL) in autologous TIL- tumor cocultures and the relation with interferon 
gamma (IFNg) levels at day 7. Cells were collected from autologous TIL- tumor cocultures for characterization at day 7. (A) 
CD4−CD8+ T cells, (B) correlation between CD4−CD8+ T cells and IFNg levels, (C) CD4+CD8 T cells, (D) correlation between 
CD4+CD8 T cells and IFNg levels. Each patient experiment was performed in triplicate and data are shown as mean+SEM. 
Statistical significance is represented as *p<0.05, **p<0.01 and ***p<0.001. OVCA, ovarian cancer.
was found on OVCA #2P (figure 5C). Ad5/3- E2F- D24- 
hTNFa- IRES- hIL2 therapy statistically reduced the pres-
ence of CD4+CD27+ TILs in OVCA #2M compared with 
the Ad5/3- E2F- D24 group (online supplementary figure 
3D). In contrast with the CD8+ TIL fraction, the concom-
itant increase in the presence of CD4+ TILs and IFNg 
levels appears to be strongly related (r=0.5567 (0.3396 
to 0.7175), p=0.0001; figure 5D). A weaker correlation 
was also found between the increase in CD16+CD56+ NK 
cells and IFNg levels in the coculture (r=0.3678 (0.1030 to 
0.5840), p=0.0062). However, on treatment with Ad5/3- 
E2F- D24- hTNFa- IRES- hIL2, only a trend (not statistically 
significant) for increased levels of NK cells was observed 
in all samples except OVCA #4 (online supplementary 
figure 3E).
Frequency of Pd-L1 in tumor cells and Pd-1 in Cd4+ tILs 
influences the magnitude of antitumor tIL reactivity
Because we observed high variability in the magnitude 
of IFNg responses among the different patient samples, 
we hypothesized that the frequency of cells expressing 
PD-1/PD- L1 checkpoint molecules could explain this 
phenomenon. We first examined the frequency and 
expression of PD- L1 in tumor cells from ex vivo tumor 
cultures (online supplementary figure 4A). Except for 
OVCA #4, there was an overall trend for reduced frequency 
of PD- L1+ tumor cells after virus treatment on day 3. On 
this day, PD- L1 expression was reduced in OVCA #3 with 
both virus and in OVCA #5 with Ad5/3- E2F- D24- hTNFa- 
IRES- hIL2. A slight increase in PD- L1 expressing cells was 
seen mostly in Ad5/3- E2F- D24 treated cultures in OVCA 
#2M and OVCA #4. After 6 days of culturing, treatment 
of OVCA #2M with Ad5/3- E2F- D24- hTNFa- IRES- hIL2 
increased the frequency of PD- L1+ tumor cells relative to 
control groups. In contrast, most samples showed either 
no variation (OVCA #2P) in the frequency of these cells 
or reduction of PD- L1+ tumor cells (OVCA #3, #4, #5). 
Surprisingly, increased expression of PD- L1+ tumor cells 
was seen in OVCA #2M, OVCA #2P and OVCA #5 (to 
some extent) treated with viruses, while a reduction in 
PD- L1 expression was observed in OVCA #3 and OVCA 
#4.
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Figure 6 Assessment of programmed death ligand 1 (PD- L1)+, CD4+ and CD8+ cell frequency in immunohistochemistry- 
stained tissues and its relation with day 7 interferon gamma (IFNg) response in cocultures of clinically relevant tumor- infiltrating 
lymphocytes (TIL) and autologous T- cell- depleted single- cell suspensions. After resection, ovarian cancer samples were fixed, 
paraffin embedded and stained for different markers by immunohistochemistry. (A) Representative image of a patient sample 
with low (OVCA #5) or high (OVCA #2) PD- L1 expression, CD4 and CD8 count (all stained in brown), (B) PD- L1 score in tumor 
cells, (C) correlation between PD- L1 in cancer cells and day 7 IFNg response in cocultures, (D) CD4+ count per high- power 
field (HPF), (E) CD8+ count per HPF, (F) correlation between CD4+ count per HPF and day 7 IFNg response in cocultures and 
(G) correlation between CD8+ count per HPF and day 7 IFNg response in cocultures. The PD- L1 score is as follows: 0=<1%, 
1=1%–4%, 2=5%–9%, 3=10%–49%, 4=>50% of PD- L1+ tumor cells. CD8+ and CD4+ cells were counted using high- power 
field at 400×.
Evaluation of PD- L1 expression, and CD4 and CD8 
count in baseline tumors (after resection) was done with 
immunohistochemistry (figure 6A). Low PD- L1 expressing 
tumors (such as OVCA #5) were also poorly infiltrated 
by CD4+ and CD8+ cells as opposed to high PD- L1 
expressing tumors where this was not observed (such as 
OVCA #2) seen (figure 6A). Baseline OVCA #1, #2 and 
#4 tumor samples scored the highest for baseline PD- L1 
expression (figure 6B) and a strong positive correlation 
was found between these scores and day 7 IFNg response 
of cocultures of clinically relevant TILs with autologous 
T- cell single- cell suspensions at day 7 (r=0.6429 [0.2375 
to 0.8576] p=0.0040; figure 6C). Following the same 
trend, these patient samples also exhibited high numbers 
of CD4+ cells (figure 6D), and, to a lower extent, CD8+ 
cells (figure 6E). Both subset counts showed also a signif-
icant positive correlation with the day 7 IFNg response in 
cocultures (both r=0.7878 (0.4964 to 0.9196), p=0.0001; 
figure 6F,G).
When we looked at CD4+PD-1+ T cells in day 14- expanded 
TILs, their frequency was lowest in OVCA #2M and OVCA 
#4 (marginally; online supplementary figure 5A), and 
this negatively influenced the IFNg response observed 
in different patient cocultures (r=−0.4859 (−0.7825 to 
−0.009699), p=0.0409; online supplementary figure 5B). 
CD8+PD-1+ TILs were observed at lower levels among 
different patient TILs (online supplementary figure 5C) 
and no relation was found between IFNg responses and 
their frequency in the latter (r=−0.3104 (−0.6869 to 0.1974), 
p=0.21; online supplementary figure 5D).
dIsCussIon
Despite the existence of multiple immune targets in the 
tumor microenvironment of OVCA, consistent clinical 
efficacy is rarely achieved when immunotherapies are 
used. In particular, TIL- based ACT has demonstrated 
discrepant results in patients with OVCA, which may 
reflect differences in patient inclusion criteria or the clin-
ical protocol.
For instance, the high response rates (82%) achieved 
in a clinical study by Aoki and colleagues may be due 
to the inclusion of a patient cohort administered with 
TILs as first- line therapy, with high- dose cyclophospha-
mide, which is active in chemotherapy- naïve OVCA. The 
authors also had another cohort which received concur-
rent cisplatin- based chemotherapy.31 Similarly, in another 
clinical study, 100% 3- year survival was achieved when the 
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infusion of TILs was performed after debulking surgery 
and adjuvant chemotherapy.32 The survival of matched 
controls was 67.5%.
In contrast, a recent clinical trial has demonstrated that 
TIL- treated patients with chemotherapy- refractory OVCA 
saw tumor progression after short- term stable disease, 
suggesting that the tumor microenvironment may be 
responsible for restricting antitumor responses mediated 
by TILs.10
In the present study, we demonstrate that Ad5/3- E2F- 
D24- hTNFa- IRES- hIL2 improves the immunological 
activation of TILs obtained from patients with OVCA. 
Primarily, these observations were possible because our 
pseudotyped (Ad5/3) oncolytic adenovirus platform 
possesses distinct properties that are highly attractive for 
the treatment of OVCAs. For instance, the fact that we 
have retargeted serotype 5 adenoviruses to serotype 3 
receptors allows the entry of Ad5/3 adenoviruses through 
receptors known to be highly upregulated in OVCA 
cells.27 This has been shown to result in efficient trans-
gene delivery and good antitumor efficacy in preclinical 
studies27 and clinical reports21 involving this malignancy.
The use of Ad5/3- E2F- D24 or Ad5/3- E2F- D24- 
hTNFa- IRES- hIL2 in our ex vivo tumor culture system 
demonstrated effective oncolytic capability despite the 
differences in the origin or subtype of the patient’s 
OVCA cells. Interestingly, the virus replication vari-
ability previously seen in patients treated with Ad5/3 
oncolytic viruses could be (in part) explained by these 
differences. Yet, to date, these hypotheses have not been 
explored in detail. It is important to note, however, that 
OVCA cells feature an aberrant p16/Rb pathway leading 
to an accumulation of intracellular free E2F proteins.33 
The fact that both viruses make use of an E2F promoter, 
should allow virus replication regardless of differences of 
histology. Moreover, the presence of transgenes in Ad5/3- 
E2F- D24- hTNFa- IRES- hIL2 did not hinder oncolysis of 
ovarian tumor cells. This concurs with the tumor cell 
killing profile that we previously observed with this virus 
in OVCA cell lines and in vivo in an orthotopic model.20 
In addition, this observation is particularly useful consid-
ering that unarmed oncolytic adenoviruses seem to result 
in inferior immunological benefit in patients with ovarian 
tumors.34 However, Ad5/3- E2F- D24- hTNFa- IRES- hIL2 
showed an apparent lack of enhanced efficacy over the 
parental backbone in this ex vivo tumor culture system. 
Notably this is not observed in vivo, where treatment with 
Ad5/3- E2F- D24- hTNFa- IRES- hIL2 demonstrates a clear 
superior curative efficacy over Ad5/3- E2F- D24 in HapT1 
(hamster pancreatic cancer) tumor- bearing hamsters.20 
Indeed, evaluation of oncolysis of immune- stimulating 
oncolytic viruses in this culture system, where the tumor 
microenvironment is present, could represent a potential 
pitfall. Because the majority of patient samples contained 
a high frequency of tumor cells, we determined overall 
tumor viability based on mitochondrial activity of the 
well. Given the T- cell stimulatory properties of Ad5/3- 
E2F- D24- hTNFa- IRES- hIL2, the possibility that the 
readout could have been influenced by T- cell prolifera-
tion cannot be discarded. Thus, one could hypothesize 
that experiments with a more sensitive assay could better 
highlight the efficacy differences between Ad5/3- E2F- 
D24- hTNFa- IRES- hIL2 and Ad5/3- E2F- D24. Importantly, 
it appears Ad5/3- E2F- D24- hTNFa- IRES- hIL2 can achieve 
superior immunological activation without loss of onco-
lytic potency.
In order to sustain durable tumor regressions, TILs 
must be capable of mounting a potent antitumor response 
and sustaining it with proinflammatory factors. This 
situation does not seem to occur readily in the ovarian 
tumor microenvironment, as it is frequent that TILs are 
unable to produce cytokines with cytotoxic effects, such 
as TNFa.35 Intriguingly, intraperitoneal administration of 
IL-2 is able to induce partial responses in patients with 
OVCA. This suggests that high levels of IL-2 are required 
at the tumor site to disrupt tolerance towards ovarian 
tumors.36
Concurring with this notion, Ad5/3- E2F- D24- hTNFa- 
IRES- hIL2 treatment of ovarian ex vivo tumor cultures 
increased the production of IFNg, a cytokine character-
istic of heightened TIL activity. Concomitant increase of 
CXCL10, a chemokine involved in TIL trafficking and 
OVCA arrest in mice,37 is concordant with SPECT/CT 
data from mice and hamsters generated by our group. 
These studies showed increased infiltration of transferred 
T cells in murine melanoma and hamster pancreatic 
tumors injected with adenoviruses coding for TNFa and 
IL-2.22 38
Interestingly, oncolytic adenovirus therapy did not 
stimulate the production of high levels of IFNb in ex vivo 
tumor cultures, which suggests that antiviral defenses 
are not easily induced in the immunosuppressive OVCA 
microenvironment. In line with these observations, de 
Queiroz and colleagues have recently reported that 
OVCA cell lines often present defects in viral sensing 
mechanisms, which contribute to higher susceptibility 
to oncolytic virus therapy.39 Slower induction of anti-
viral immunity could offer some advantages to oncolytic 
virus therapy, if the virus is able to replicate more. Yet, 
since we have previously observed that type I IFN path-
ways can induce resistance to Ad5/3 oncolytic adenovirus 
therapy in an in vivo human OVCA xenograft model,40 it 
is also possible that increased immune stimulation could 
increase antiviral responses.
Of note, the reduction of suppressive cytokines (IL-6, 
TGF- b1 and arginase) on Ad5/3- E2F- D24- hTNFa- 
IRES- hIL2 therapy is particularly relevant, considering 
that increased levels of these cytokines are implicated in 
the suppression of antitumor TIL activity in a number 
of malignancies, including OVCA.41 In particular, 
TGF- b1 is reported to increase the invasive potential of 
OVCA cells.42 Besides the negative effects on the adap-
tive immune system, such cytokines are a functional 
signature of infiltrating MDSCs and Tregs.41 Decreased 
activity of MDSCs is in line with previous observations 
where intratumororal injections of TNFa and IL-2- coding 
copyright.














13Santos JM, et al. J Immunother Cancer 2020;8:e000188. doi:10.1136/jitc-2019-000188
Open access
adenovirus, combined with T- cell therapy, led to a reduc-
tion in functional MDSCs in mice developing sponta-
neous melanoma.43
Skewing of the cytokine milieu towards Th1 signals 
is indicative of an ongoing inflammatory antitumor 
response, which in OVCA is predominantly associated 
with CD8+ and CD4+ TIL activity.41 In a recent study, 
Owens and colleagues found that CD4+CD69+ TILs are 
capable of inducing high levels of Th1 cytokines which 
may explain the tight positive correlation between CD69 
expression in CD4+ TILs, and the levels of immune 
stimulatory cytokines found in cultures treated with 
Ad5/3- E2F- D24- hTNFa- IRES- hIL2.44 This observation is 
appealing since active CD4+ TILs predict improved clin-
ical outcome,45 supporting the use of Ad5/3- E2F- D24- 
hTNFa- IRES- hIL2 in this indication.
On another note, the decrease in the frequency of 
CD4+CD25+ T cells in cultures treated with virus could 
indicate a drop in recently activated TILs. However, the 
effects of virus- derived IL-2 are noticeable as CD25 expres-
sion remained high in most patient cultures treated with 
Ad5/3- E2F- D24- hTNFa- IRES- hIL2. Considering that 
CD25 expression decreases after its peak at 72 hours,46 it 
is conceivable that IL-2- coding oncolytic adenoviruses are 
capable of ensuring continuous activation of T cells.
The generation and expansion of TILs for therapeutic 
application can be achieved with high reproducibility 
in different tumor types,4 and OVCA is no exception. A 
recent study reported that TIL culture resulted in grafts 
with a high CD4- to- CD8 cell ratio.47 In contrast, we and 
others have frequently seen the inverse situation, perhaps 
reflecting variations in the TIL production protocols,44 
such as the concentration of IL-2 used.47
In ACT with TILs, IL-2 is used for the in vivo main-
tenance of the TIL graft activity.4 Thus, production of 
IL-2 by Ad5/3- E2F- D24- hTNFa- IRES- hIL2 may explain 
the increase of TIL- derived IFNg seen (figure 4). In the 
context of immunotherapy of OVCA, IFNg production is 
beneficial since it has been shown by others to promote 
the upregulation of antigen presentation machinery and 
induce direct apoptosis in OVCA tumor cells.48
Interestingly, as noted in melanoma and OVCA,44 47 our 
data suggest that the CD4+ fraction may contain potent 
tumor- reactive T cells. In line with this concept, Pedersen 
and colleagues also reported high expression of human 
leucocyte antigen class II in OVCA patient biopsies, 
suggesting the involvement of CD4+ T cells in antitumor 
immunity in this indication.10 Cytotoxic CD4+ T cells also 
play a major role in eliminating virus- infected cells49 and, 
since they can be present in the expanded TIL product, 
they could have had played a role in the reactivity seen 
here.
Notably, there was high variability in the magnitude of 
TIL- IFNg responses across different patients although 
this was not influenced by the unwanted frequency of 
Treg TIL cultures. In agreement, indirect evidence shows 
that treatment of patients with metastatic melanoma 
using adoptive transfer with enriched ‘young’ CD8+ TILs 
did not result in significant clinical benefit in comparison 
with unselected ‘young’ TILs.50 It appears, however, that 
reconstitution of endogenous Tregs during IL-2 postcon-
ditioning is a key driver for the negative outcome of ACT 
with TILs.51
Recently, the PD-1/PD- L1 axis has drawn extensive 
attention due to its role in the negative regulation of anti-
tumor immune responses in many tumor types, including 
OVCA.52 Indeed, expression of PD- L1 at the tumor and 
PD-1 in TILs has been deemed to compromise the efficacy 
of adoptive TIL therapy of patients with OVCA in a recent 
clinical trial.10 In high- grade serous OVCA, PD- L1+ cells 
(containing also tumor cells) are positively associated with 
infiltration of TILs, thus providing a favorable prognostic 
factor.53 This is not surprising since PD- L1 expression in 
tumors also defines a previously immunologically active 
tumor,54 which has developed the ability to silence adap-
tive immunity. Additionally, the fact that the frequency of 
CD4+PD-1+ TILs, not CD8+PD-1+ TILs, negatively influ-
ences the IFNg response, reinforces the importance of 
CD4+ TILs in the antitumor response in OVCA. Further 
experiments would be required to detail the exact mech-
anisms of this immunological response. Together with 
our data, these findings may explain the susceptibility of 
some samples to immunotherapy with expanded TILs. It 
is important to note that even though the frequency of 
PD- L1+ tumor cells and CD4+PD-1+ TILs may determine 
the outcome of T- cell- based immunotherapy, Ad5/3- E2F- 
D24- hTNFa- IRES- hIL2 was able unleash significant TIL 
antitumor responses independently of these factors.
Perhaps the biggest challenge with using patient- 
derived ex vivo tumor cultures to study the immunolog-
ical potency of oncolytic adenoviruses is the absence of 
a full immune system. The fact that this is an isolated 
culture system under- represents the dynamics of adaptive 
immune responses. Influx of T cells is not possible and 
generation of new T- cell responses is confined to the local 
repertoire of antigen- presenting cells potentially skewing 
the efficacy of cytokine- coding adenovirus aiming at stim-
ulating T cells. Additionally, this system lacks a 3D struc-
ture preventing us from determining the real kinetics 
of virus dissemination. It is important, however, to put 
these flaws in the context of the available tools to study 
immune- stimulating oncolytic adenoviruses in OVCA. 
First, oncolytic adenoviruses only fully replicate in human 
and, partially, in Syrian hamsters (Mesocricetus auratus). 
While it is relatively easy to establish human tumor xeno-
grafts (not patient derived) in immunocompromised 
mice, it lacks an immune system, thus only virus replica-
tion can be studied in this model. On the other hand, 
we could not use Syrian hamsters because, to date, the 
species lacks an OVCA tumor model and reagents that 
could allow us to gain further insight into the immuno-
logical impact of our oncolytic adenovirus platform. On 
the other hand, immunocompetent mouse models offer 
an incomplete vision on the immunological effects of 
oncolytic adenovirus because, while cytokine transgene 
expression is possible, lytic replication is not achieved. 
copyright.














14 Santos JM, et al. J Immunother Cancer 2020;8:e000188. doi:10.1136/jitc-2019-000188
Open access 
Hence, ex vivo tumor cultures offer a valuable method to 
determine in- depth characterization of the local effects 
of immune- stimulating adenoviruses in human substrates 
while taking into account the heterogeneity of the human 
tumors.
ConCLusIons
In conclusion, while Ad5/3 chimeric oncolytic adenovi-
ruses in general provide an efficacious treatment modality 
for OVCA,17 21 our findings indicate that the introduction 
of TNFa and IL-2 is appealing for promotion of substantial 
immunological activation of locoregional TILs. Increase 
in CXCL10 suggests that local virus replication can also 
recruit T cells from further away compartments, such as 
the blood, for example. Furthermore, the use of oncolytic 
adenoviruses coding for TNFa and IL-2 reconfigures the 
ovarian tumor microenvironment to enhance the tumor 
reactivity of clinically relevant OVCA TILs.
Together with the enhanced in vivo efficacy observed by 
us and others,20 24 these data strengthen the rationale for 
a clinical trial where Ad5/3- E2F- D24- hTNFa- IRES- hIL2 
would be administered in patients with OVCA receiving 
TIL therapy, in order to improve clinical responses. Incur-
able OVCA frequently remains intraperitoneal, which 
creates a strong rationale for intraperitoneal delivery. 
The peritoneal cavity can be seen as a large immunolog-
ical organ.55 These features make OVCA an appealing 
target for oncolytic immunotherapy.
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